Navigation Links
Updated Phase 1 Data for Exelixis' XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
Date:10/23/2007

lasting from three months to up to 20 months, including nine patients with stable disease for more than six months.

Preliminary analyses of pharmacodynamic samples show changes in VEGF-A, sVEGFR2 and PIGF consistent with effects observed with other antiangiogenic agents. Preliminary pharmacokinetic analyses of nine dose levels (0.08-11.52 mg/kg) indicate a long half-life of XL184 of 59 to 136 hours.

"In this study of XL184, we observed partial responses in patients with medullary thyroid cancer and tumor shrinkage in a patient with papillary renal cell cancer, which frequently have mutational activation or overexpression of RET or MET, respectively," said George A. Scangos, Ph.D., president and chief executive officer of Exelixis. "We believe the data to date demonstrate the potential of simultaneous inhibition of MET, RET, and VEGFR, and validate our ability to discover and develop compounds that simultaneously inhibit critical pathways in cancer. We are excited about the potential of XL184 to provide effective therapy for patients with a variety of tumor types, and we intend to advance XL184 into a phase 2 program by the end of 2007."

To date, five dose-limiting toxicities (DLTs) have been reported, including Grade 3 palmar/plantar erythema, Grade 3 AST elevation, Grade 3 ALT elevation, and Grade 3 lipase elevation in patients dosed at 11.52 mg/kg, as well as a DLT of Grade 2 mucositis in a patient dosed at 265 mg. Serious adverse events (AEs) considered possibly or probably related to XL184 include one report each of Grade 3 fatigue and Grade 3 pulmonary embolism. Dose escalation continues in order to determine a maximum tolerated dose (MTD).

About the Trial

This phase 1, open-label, dose-finding trial is being conducted in patients aged 18 years or older with histologically confirmed advanced solid malignancy or lymphoma that is metastatic or unresectable and for which alternative therapies do not exist or are no longer effective. P
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
3. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
4. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
5. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
6. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
7. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
8. Media Advisory: ACC Updated Schedule
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Research and Markets has announced the addition of ... by Application & by Region- Global Trends & Forecasts to ... demand for membranes is estimated to increase at a CAGR ... Membrane technology was first commercialized in the 1960s ... kidney dialysis. In modern times, membranes find extensive application in ...
(Date:8/19/2014)... 19, 2014  Boehringer Ingelheim today announced that ... for review the New Drug Application (NDA) for ... delivered via the Respimat ® inhaler for ... of airflow obstruction in patients with chronic obstructive ... Tiotropium + olodaterol FDC will not be indicated ...
(Date:8/19/2014)... According to Kalorama Information, electronic medical records ... Data in healthcare a reality, and this a factor ... American Recovery and Reinvestment Act, the U.S. government dedicated ... penalties will start applying soon for use of paper ... study of the EMR industry, EMR 2014: The ...
Breaking Medicine Technology:Global Membranes (MF, RO, UF, Gas Separation, Dialysis, NF) Market - Forecasts to 2019 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3
... Biosciences, a privately held company leading the development of ... McDonald, MBA, Senior Vice President and Chief Business Officer, ... Pennsylvania Convention Center in Philadelphia, Pennsylvania.  Ms. McDonald,s presentation ... November 10 in the Life Science Room #106AB and ...
... Nov. 3, 2010 Caliper Life ... leading provider of tools and services for drug ... collaboration with Sony DADC Austria AG for the ... next generation microfluidics products. The agreement combines Sony ...
Cached Medicine Technology:Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania 2Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania 3Caliper Life Sciences and Sony DADC Collaborate to Develop Plastic Microfluidic Solutions 2
(Date:8/20/2014)... Kowa Optimed returns after a short hiatus to ... SL-17 portable slit lamp. , The SL-17 has been ... by an illuminated thumb wheel for easy adjustments even ... AAA rechargeable and dry cell batteries, which is an ... specifically for the device. The new Sl-17 base design ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Riverside Health ... Dameron , who joined its Warsaw Medical Arts team ... specialized in Family Medicine, is accepting new patients. , ... of Medicine, completed his residency at the Mountain Area ... to Virginia. , “I really like the rural aspect ...
(Date:8/20/2014)... 20, 2014 This agreement will ... software defined networking, high availability cloud enablement, service, ... Resellers, while allowing OPEN-V to sell storageFOUNDRY’s expanding ... to work with OPEN-V on this distribution agreement ... manager distribution channels at storageFOUNDRY. "Nautilus is a ...
(Date:8/19/2014)... As moms and dads prepare their children to go back ... routine of dropping their little ones off at daycare with ... encourages them to use the opportunity to implement a new ... explains, “Kids have small tummies, short attention spans, and a ... handouts, use snack time as another daily opportunity to incorporate ...
(Date:8/19/2014)... (PRWEB) August 20, 2014 Midtown Dentistry in ... amalgam-free dental office. All patients with cavities, or with ... latest white fillings that can safely repair and restore teeth. ... the very latest materials, all of which are completely amalgam ... safe for use by the FDA for adults and children ...
Breaking Medicine News(10 mins):Health News:Kowa Optimed (Booth MS13043) to Debut New Portable Slit Lamp at 2014 Vision Expo West in Las Vegas, Nevada 2Health News:Riverside Warsaw Medical Arts’ Dr. William Dameron Accepting New Patients 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 2Health News:storageFOUNDRY and Open-V OzoneStack Announce Bilateral Distribution Agreement 3Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 3Health News:Midtown Dentistry Announces It Is Now an Amalgam-Free Office 2
... ... Save Lives in Healthcare Facilities and for Senior Care at Home. , ... (PRWEB) January 26, 2010 -- New inexpensive technologies ... effect of falls particularly in the population now approaching 60 and above. New personal use ...
... ... Cancer Care Delivery System , ... Washington, DC (Vocus) January 26, 2010 -- Community oncologists nationwide, under the ... urge President Obama and lawmakers to reverse drastic cuts in reimbursement for cancer care ...
... , Jan. 26 Milliman Care Guidelines LLC, ... that help health plans, hospitals and other clients optimize the ... software.   , The Care Guidelines promote quality ... on annually updated evidence, thus enabling informed and consistent clinical ...
... ... launched three new document scanners with rated speeds up to 60 images per minute ... models include a 2-Year manufacturer’s warranty, BulletScan Manager Software, and ABBYY FineReader® ... ...
... ... they are now offering Trek’s Ride+ electric assist bikes to their guests. By being one of ... opening up a new world of cycling vacations to a wider range of riders. Now anyone ... ...
... OAK BROOK, Ill. Preoperative computed tomography (CT) may ... with suspected acute appendicitis, according to a new study ... Radiology . "We found that rising utilization of ... in CT technology, coincided with a significant decrease in ...
Cached Medicine News:Health News:Medical Nurse Training, Inc and SaferFalls.com Announce New Products/Technologies to Save Lives in Healthcare Facilities and for Senior Home Care. 2Health News:Medical Nurse Training, Inc and SaferFalls.com Announce New Products/Technologies to Save Lives in Healthcare Facilities and for Senior Home Care. 3Health News:Community Oncologists Launch Petition to Stop Drastic Cancer Care Cuts 2Health News:Community Oncologists Launch Petition to Stop Drastic Cancer Care Cuts 3Health News:Milliman Care Guidelines Offers Online Interrater Reliability Tool and Training 2Health News:Milliman Care Guidelines Offers Online Interrater Reliability Tool and Training 3Health News:Milliman Care Guidelines Offers Online Interrater Reliability Tool and Training 4Health News:iVina Expands BulletScan Document Scanner Product Line Powered by ABBYY FineReader Technology 2Health News:iVina Expands BulletScan Document Scanner Product Line Powered by ABBYY FineReader Technology 3Health News:iVina Expands BulletScan Document Scanner Product Line Powered by ABBYY FineReader Technology 4Health News:Trek Travel Introduces Trek's Ride+ Electric Assist Bikes to Cycling Vacations 2Health News:Preoperative CT useful for younger women with suspected appendicitis 2
... to the National Academy of ... use of cardiac markers in ... is definitive of acute myocardial ... assay was designed for rapid ...
A fluorogenic enzyme-linked immunoassay (ELISA) for the quantitative measurement of myoglobin in human serum or plasma aiding in the diagnosis of acute myocardial infarction (AMI). Features : Dry che...
Clinical marker immunoassay kit for detection of Myoglobin....
AxSYM Myoglobin is a Microparticle Enzyme Immunoassay (MEIA) for the quantitative determination of myoglobin in human serum or plasma on the AxSYM System....
Medicine Products: